NKGen Biotech, Inc. Common Stock (NKGN)

NKGen Biotech, Inc. Common Stock (NKGN) is a company listed on the NASDAQ.

As of Oct 23, 2026: market cap $7.8M; returns 1 day +300.0%.

NKGen Biotech, Inc. is a clinical-stage biotechnology company that focuses on developing and commercializing cell-based therapies, particularly those involving natural killer (NK) cell technologies, for the treatment of neurodegenerative and oncological diseases. Their primary focus is on addressing unmet medical needs within the biopharmaceutical market.

Groups NKGN belongs to

• Biotechnology
• Clinical Stage Biotech
• Healthcare
• Biopharmaceutical
• Autologous Cell Therapy
• Neuroscience
• Oncology
• Alzheimer's Disease
• Clinical Stage
• CNS Disorders
• Life Sciences
• Unmet Medical Needs

NKGN financial model: income statement, cash flow and balance sheet